House
Sign inCreate account
Drug lookup
Drug reference

duvelisib

PI3Kδ and PI3Kγ inhibitor · Antineoplastic agent

PI3Kδ and PI3Kγ inhibitorAntineoplastic agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
D
FDA category + note
Top interactionssee all 12 →
  • AcalabrutinibSevereDatabaseDDInter
  • AdalimumabSevereDatabaseDDInter
  • AlfentanilSevereDatabaseDDInter
  • ApalutamideSevereDatabaseDDInter

Mechanism

Duvelisib is an orally bioavailable inhibitor of PI3Kδ and PI3Kγ. The potency of duvelisib against the β and α isoforms is lower.

Indications

relapsed or refractory CLL, SLL, or FL after at least two prior therapies

Pharmacokinetics

Half-life
4.7 h (elimination)
Metabolism
CYP3A4

Side effects

Serious
  • infections (31% of patients)
  • diarrhea and colitis (18%)
  • pneumonitis (5%)

Pregnancy & lactation

Pregnancy

D

Drug interactions

Acalabrutinib
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Adalimumab
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Alfentanil
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Apalutamide
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Atazanavir
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Avanafil
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Avapritinib
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Baricitinib
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Benzhydrocodone
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Boceprevir
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Bosutinib
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Brexpiprazole
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Related guidelines

Heart failure in diabetes
RSSDI · Cardiology · 2023
Hypertension in adults
ICMR · Cardiology · 2019
Generalised anxiety disorder and panic disorder
NICE · Psychiatry · 2020
Hypertrophic cardiomyopathy
ESC · Cardiology · 2026
Diabetes management in chronic kidney disease
KDIGO · Nephrology · 2022

Ask House about duvelisib

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspaceAsk House about this drug

Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team